Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on May 11, 2026 has been entered.
Claim amendment filed on April 14, 2026, is acknowledged. Claims 1-12, 14-17 and 20 are pending in this application.
Claims 18-19 have been cancelled.
Claims 4-12 remain withdrawn from consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected inventions, there being no allowable generic or linking claim.
Claims 1-3, 14-17 and 20 are examined on the merits in this office action.
Withdrawn Rejections
Rejection of claims 1-3 and 14-16 under 35 U.S.C. 102(a)(1) as being anticipated by Wu patent (US Patent No. 6312755, filed with IDS), is hereby withdrawn in view of Applicant’s amendment to the claims.
Rejection of claim 18 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is hereby withdrawn in view of Applicant’s cancellation of the claim.
Rejection of claims 1-3 and 14-20 under 35 U.S.C. 103 as being unpatentable over Wu patent (US Patent No. 6312755, filed with IDS) in view of Davis et al (US 2005/0142249, cited in the previous office action), is hereby withdrawn in view of Applicant’s amendment to the claims.
Please note, the specification has not been checked to the extent necessary to determine the presence of all possible error. Applicant's cooperation is required in correcting any errors of which applicant may become aware in the specification. MPEP § 608.01.
New Rejections
35 U.S.C. 112(b)
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 20 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 20 recites the limitation "the blend" in the claim, line 2. There is insufficient antecedent basis for this limitation in the claim. Claim 20 depends from claim 1. Claim 1 recites, “
PNG
media_image1.png
502
590
media_image1.png
Greyscale
”. Claim 1 does not recite “a blend”. Therefore, there is lack of antecedent basis.
35 U.S.C. 112(d)
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claim 17 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Claim 17 recites, “The method of claim 1, wherein the synthetic nutritional composition comprises the alpha-lactalbumin enriched WPE in a concentration between 0.8 to 10 g/L.” Claim 17 depends from claim 1. Claim 1 recites, “
PNG
media_image1.png
502
590
media_image1.png
Greyscale
”. Claim 1 already recites “0.8 to 10 g/L of alpha-lactalbumin enriched WPE”. Therefore, claim 17 does not further limit instant claim 1.
U.S.C. 102
16. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
17. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
18. Claim(s) 1-3, 14-17 and 20 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Brosnan et al (WO 2019/122363, filed with IDS).
19. Brosnan et al teach blending appropriate quantities of the alpha-lactalbumin-enriched whey protein concentrate with skimmed milk, lactose, vegetable oils and fat soluble vitamins in water…The mixture may then be homogenized and cooled…The mixture may then be standardized with deionized water to a final total solids concentration of about 120 to about 135 for example about 123 grams per liter, which is equivalent to about 670 kcal per liter (see p. 8, lines 30-42), meeting the limitation of instant claims 1, 3, 15-17 and 20. Brosnan et al teach that the synthetic nutritional composition comprises the alpha-lactalbumin enriched WPE in a concentration within a range of 0.8 to 10 g/L, for example, 0.8 to 8, 0.8 to 5 g/L, 0.85 to 4.5 g/L, 3 to 4.5 g/L (see p. 6, lines 25-26), meeting the limitation of instant claims 1 and 17. Brosnan et al teach that in a preferred embodiment, the synthetic nutritional composition has a low total protein content…the protein content is of at most 20 g/L…at most 18 g/L…at most 15 g/L…between 5 and 20 g/L…8 to 18 g/L…10 to 16 g/L…11 to 15 g/L…(see p. 7, lines 25-31), meeting the limitation of instant claim 1. Brosnan et al teach that the synthetic nutritional composition for an infant or child can also comprise any other ingredients or excipients known to be employed in the type of synthetic nutritional composition in question e.g., infant formula (see p. 7, lines 33-35), meeting the limitation of instant claim 14.
With respect to the limitation in the preamble of claim 1, “A method for preparing a synthetic nutritional composition having a final concentration of cholesterol found in human breast milk and comprising an alpha-lactalbumin enriched whey protein extract (WPE)...”, please note that MPEP 2111.02 II states "a preamble generally is not limiting when the claim body describes a structurally complete invention such that deletion of the preamble phrase does not affect the structure or steps of the claimed invention." In the instant case, the preamble does not affect the method steps. The preamble in this case recites a statement of purpose or use, and therefore was not treated as a claim limitation.
With respect to claims 3 and 16, the claims 3 and 16 recite end results. Thus, since Brosnan et al teach ALL of the active method steps of blending the same amount of alpha-lactalbumin enriched WPE with skimmed milk powder, lactose, vegetable oils, and fat soluble vitamins in water, the method taught by Brosnan et al would have the same end result, meeting the limitation of instant claims 3 and 16.
With respect to claim 15, Brosnan et al is silent as to an isolated cholesterol. Therefore, there is no isolated cholesterol in the composition.
Since Brosnan et al teach ALL of the active method steps of instant claims, Brosnan et al anticipates instant claims 1-3, 14-17 and 20.
20. Claim(s) 1-3, 14-17 and 20 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Brosnan et al (WO 2019/122363, filed with IDS).
The applied reference has a common assignee and Inventor (Jonathan O’Regan) with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement.
21. Brosnan et al teach blending appropriate quantities of the alpha-lactalbumin-enriched whey protein concentrate with skimmed milk, lactose, vegetable oils and fat soluble vitamins in water…The mixture may then be homogenized and cooled…The mixture may then be standardized with deionized water to a final total solids concentration of about 120 to about 135 for example about 123 grams per liter, which is equivalent to about 670 kcal per liter (see p. 8, lines 30-42), meeting the limitation of instant claims 1, 3, 15-17 and 20. Brosnan et al teach that the synthetic nutritional composition comprises the alpha-lactalbumin enriched WPE in a concentration within a range of 0.8 to 10 g/L, for example, 0.8 to 8, 0.8 to 5 g/L, 0.85 to 4.5 g/L, 3 to 4.5 g/L (see p. 6, lines 25-26), meeting the limitation of instant claims 1 and 17. Brosnan et al teach that in a preferred embodiment, the synthetic nutritional composition has a low total protein content…the protein content is of at most 20 g/L…at most 18 g/L…at most 15 g/L…between 5 and 20 g/L…8 to 18 g/L…10 to 16 g/L…11 to 15 g/L…(see p. 7, lines 25-31), meeting the limitation of instant claim 1. Brosnan et al teach that the synthetic nutritional composition for an infant or child can also comprise any other ingredients or excipients known to be employed in the type of synthetic nutritional composition in question e.g., infant formula (see p. 7, lines 33-35), meeting the limitation of instant claim 14.
With respect to the limitation in the preamble of claim 1, “A method for preparing a synthetic nutritional composition having a final concentration of cholesterol found in human breast milk and comprising an alpha-lactalbumin enriched whey protein extract (WPE)...”, please note that MPEP 2111.02 II states "a preamble generally is not limiting when the claim body describes a structurally complete invention such that deletion of the preamble phrase does not affect the structure or steps of the claimed invention." In the instant case, the preamble does not affect the method steps. The preamble in this case recites a statement of purpose or use, and therefore was not treated as a claim limitation.
With respect to claims 3 and 16, the claims 3 and 16 recite end results. Thus, since Brosnan et al teach ALL of the active method steps of blending the same amount of alpha-lactalbumin enriched WPE with skimmed milk powder, lactose, vegetable oils, and fat soluble vitamins in water, the method taught by Brosnan et al would have the same end result, meeting the limitation of instant claims 3 and 16.
With respect to claim 15, Brosnan et al is silent as to an isolated cholesterol. Therefore, there is no isolated cholesterol in the composition.
Since Brosnan et al teach ALL of the active method steps of instant claims, Brosnan et al anticipates instant claims 1-3, 14-17 and 20.
CONCLUSION
No claim is allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JULIE HA whose telephone number is (571)272-5982. The examiner can normally be reached Monday-Thursday 5:00 am- 6:30 pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, LIANKO GARYU can be reached at 571-270-7367. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JULIE HA/Primary Examiner, Art Unit 1654
10/27/2026